Trial Profile
A Phase I / 2, Multicenter, Open-label, Single-dose, Dose-ranging Study to Assess the Safety and Tolerability of SB-318, a rAAV2/6-based Gene Transfer in Subjects With Mucopolysaccharidosis I (MPS I)
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs SB 318 (Primary)
- Indications Mucopolysaccharidosis I
- Focus Adverse reactions
- Acronyms EMPOWERS
- Sponsors Sangamo Therapeutics
- 01 Dec 2021 Status changed from active, no longer recruiting to discontinued.
- 21 Oct 2021 Planned primary completion date changed from 31 Oct 2021 to 30 Nov 2021.
- 16 Sep 2021 Planned primary completion date changed from 1 Jun 2021 to 31 Oct 2021.